Antenatal progesterone to prevent preterm birth

The Lancet

Volumn 373, Issue 9680, 2009, Pages 2000-2002

  Doyle, Lex W ^a  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MAGNESIUM SULFATE; PROGESTERONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FETUS; GESTATIONAL AGE; HUMAN; INFANT; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE PREGNANCY; NEUROLOGIC DISEASE; NEUROPROTECTION; PREMATURE LABOR; PRENATAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 66649123547     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61077-1     Document Type: Note

References (12)

1. Saigal S., and Doyle L.W. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 371 (2008) 261-269
2. WHO. International Clinical Trials Registry Platform Search Portal. http://apps.who.int/trialsearch/ (accessed May 26, 2009).
3. Rouse D.J., Caritis S.N., Peaceman A.M., et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 357 (2007) 454-461
4. Norman J.E., Mackenzie F., Owen P., et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet (2009) 10.1016/S0140-6736(09)60947-8 published online June 11.
5. Dodd J.M., Flenady V., Cincotta R., and Crowther C.A. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev 1 (2006) CD004947.
6. Dodd J.M., Flenady V.J., Cincotta R., and Crowther C.A. Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol 112 (2008) 127-134
7. Northen A.T., Norman G.S., Anderson K., et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 110 (2007) 865-872
8. Crowther C.A., Hiller J.E., Doyle L.W., and Haslam R.R. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 290 (2003) 2669-2676
9. Crowther C.A., Doyle L.W., Haslam R.R., Hiller J.E., Harding J.E., and Robinson J.S. Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. N Engl J Med 357 (2007) 1179-1189
10. Crowther C.A., Hiller J.E., and Doyle L.W. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 4 (2002) CD001060.
11. Doyle L.W., Crowther C.A., Middleton P., Marret S., and Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 1 (2009) CD004661.
12. Doyle L.W., Crowther C.A., Middleton P., and Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet Gynecol 113 (2009) 1327-1333